Skip to Content

AML patients with FLT3-ITD and wild-type NPM1 has a significant improvement of LFS, OS and GRFS

Ali Bazarbachi, MD, and PhD at the American University of Beirut in Lebanon, presents in this MEDtalk a report from the EBMT Acute Leukemia Working Party, showing improved post-transplant outcomes for AML patients with intermediate karyotype FLT3-ITD and wild type NPM1.

Ali Bazarbachi

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top